Dbv Technologies SA 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
DBV Technologies reports positive Phase 3 VITESSE results for its Viaskin Peanut patch in children aged 4-7, secures significant financing, and outlines accelerated regulatory pathways for both toddler and child populations in the U.S.
NASDAQ
10-K/A: DBV Technologies Files Amendment to 10-K to Update Beneficial Ownership and Registered Securities
DBV Technologies amends its annual report on Form 10-K to update beneficial ownership information and the description of registered securities.
NASDAQ
DBV Technologies provides an overview of its ordinary shares, American Depositary Shares, corporate governance practices, and executive compensation in its amended 10-K filing.
NASDAQ
10-K: DBV Technologies Reports Full Year 2024 Results, Outlines Path to Potential Viaskin Peanut Approval
DBV Technologies reports its full year 2024 results and provides updates on its Viaskin Peanut program, including a potential accelerated approval pathway.
NASDAQ
DBV Technologies' 10-K filing provides a comprehensive overview of the company's financial status, clinical program advancements, and regulatory strategies, particularly for its Viaskin technology.